• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
  • View Item
  •   LillOA Home
  • Liste des unités
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Profound, durable and mgmt-independent ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique: Article original
DOI :
10.1002/ijc.32069
PMID :
30549269
Permalink :
http://hdl.handle.net/20.500.12210/75104
Title :
Profound, durable and mgmt-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition
Author(s) :
Le Rhun, Emilie [Auteur]
Von Achenbach, Caroline [Auteur]
Lohmann, Birthe [Auteur]
Silginer, Manuela [Auteur]
Schneider, Hannah [Auteur]
Meetze, Kristan [Auteur]
Szabo, Emese [Auteur]
Weller, Michael [Auteur]
Journal title :
International journal of cancer
Abbreviated title :
Int. J. Cancer
Publication date :
2018-12-14
ISSN :
1097-0215
Keyword(s) :
glioma
senescence
chemotherapy
MGMT
resistance
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
TG02 is a novel cyclin-dependent kinase (CDK) inhibitor and thought to act mainly via CDK-9 inhibition-dependent depletion of short-lived oncoproteins such as MCL-1 or c-MYC. We studied the activity of TG02 in 9 human ...
Show more >
TG02 is a novel cyclin-dependent kinase (CDK) inhibitor and thought to act mainly via CDK-9 inhibition-dependent depletion of short-lived oncoproteins such as MCL-1 or c-MYC. We studied the activity of TG02 in 9 human long-term glioma cell lines (LTC) and 5 glioma-initiating cell lines (GIC) using various cell death assays in vitro and in the LN-229 LTC and ZH-161 GIC models in vivo. TG02 exhibits strong anti-tumor cell activity with EC50 concentrations in the nanomolar range. Median survival in the LN-229 and ZH-161 models was moderately prolonged by TG02. Neither constitutive CDK levels nor those of MCL-1 or c-MYC correlated with sensitivity to TG02. Cdk-9 or cdk-5 gene silencing alone did not fully reproduce the effects of TG02. C-myc gene silencing inhibited cell growth, but did not modulate TG02 activity. Electron microscopy revealed cell death to be essentially apoptotic. High concentrations of TG02 induced annexin V binding and minor caspase 3 cleavage, but the pan-caspase inhibitor, zVAD-fmk, or BCL-2 or MCL-1 gene transfer only moderately attenuated TG02-induced cell death, and caspase inhibition did not prevent loss of MCL-1 or c-MYC. TG02 activity was independent of O(6) -methylguanine DNA methyltransferase expression. Repetitive exposure to TG02 did not generate an acquired TG02 resistance phenotype, but accumulation of MCL-1, loss of c-MYC, or senescence. TG02 is a highly potent apoptosis-inducing agent in glioma cells in vitro. Caspase inhibition does not rescue TG02-treated cells and repetitive exposure fails to confer acquired resistance, supporting the clinical evaluation of TG02 in glioblastoma.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
INSERM
Université de Lille
Collections :
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Submission date :
2022-06-15T13:58:53Z
Université de Lille

Mentions légales
Université de Lille © 2017